Skip to content

Our 2011 American Society of Hematology (ASH) Coverage: Part 1

December 19, 2011

Part 1 of our 2011 American Society of Hematology (ASH) coverage focus on a sampling of the news shared at this recent conference. Part 2, coming soon, will feature our patient advocate liaison, Brenda Hawkes, and her experiences at this event.

“The Seed and the Soil” In The Search for the Cure from the International Myeloma Foundation
We highlighted this post on our social networks, but this is well worth reading for those not as familiar with Myeloma.

Cancer Drug Coverage Parity Act from Living With Multiple Myeloma
Brenda Hawkes learned about this act, which seeks to make oral chemotherapies billable the same way that IV chemotherapies are, at ASH 2011. Though this link was written before the conference, it was covered there.

What’s hot at ASH 2011? from
This post was written before the author went out to the meetings, but highlights some of the important topics that were interesting to the author. Some key notes include Jakafi (ruxolitinib) receiving FDA approval; this drug can be used to treat complications of Myelofibrosis. Many new drugs are now on trial or pending approval as well and can make a difference for Myeloma and Lymphoma patients.

Obinutuzumab Bests Rituximab in Patients with Relapsed Non-Hodgkin Lymphoma and Encouraging Findings Reported for Ibritumomab Tiuxetan in Follicular Lymphoma from Cancer Network
In the first comparison trial between these two drugs, Obinutuzumab was shown to be more effective than Rituximab. The researchers decided, in addition, that Obinutuzumab could be safely used in conjunction with chemotherapy for this population.
Ibritumomab Tiuxetan trials also yielded results that demonstrated potential.

New Findings for Vaccine Isotypes and Blood Cancer Trials from GEN
Researchers believe they may be able to use immunotherapies successfully to treat blood cancers. This could be an important step forward.

Key Pressentations and Meeting Takeaway Points from OncLive
Check out these video interviews from the conference.

Study Favors As-Needed Treatment Over Maintenance Therapy for Patients with Follicular Lymphoma from an ASH press release
Researchers found that asymptomatic follicular Lymphoma patients benefited more from drug therapy as-needed, the traditional form of treatment for these patients.

Jack Aiello’s Updates from the International Myeloma Foundation
These recaps, written by a Myeloma patient, present the viewpoint of a person with Myeloma looking at the myriad of treatment options available out there. Mr. Aiello noted that many doctors seem better aware of causes of relapsed or refractory treatment, when the therapy stops working or never was effective respectively.

Pat Killingsworth’s Updates from the International Myeloma Foundation (also affiliated with Living With Multiple Myeloma)
These updates present the perspective of a relapsed Myeloma patient also looking at the variety of therapies out there with a mind on how the new options could benefit his specific case. There was a wealth of information on new therapy research at this event.

ASH Updates from Oncology Nurse Advisor
There’s a lot to take in here but some key points include Lenalidomine’s potential use in maintenance therapy for relapsed/advanced Cutaneous T-Cell Lymphoma,  positive results for Myelodysplastic Syndrome (MDS) when treated with Erlotinib, and that there were minimal complications for both  mother and unborn child when pregnant women with Hodgkin’s and non-Hodgkin’s Lymphoma received standard chemotherapy during the 2nd and/or 3rd trimester.

What Is Myelofibrosis? from Novartis
Watch this short (under 2 minutes!) video and learn more about this disease.

Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response from an ASH press release
Much of the new research presented at ASH 2011 focused on individualized treatment for patients that can take advantage of the many new possibilities for both of these diseases.

Stay tuned for Part 2, featuring Brenda Hawkes’ personal viewpoint on ASH 2011 and the events she attended!

As always, to find out more about how we might be able to help you, please call our toll-free advocacy hotline at (855) 284-4642.

Justine Dolorfino is a Patient Advocacy Social Media Representative for Diplomat Specialty Pharmacy. You can get in touch with Diplomat about your needs at our toll-free hotline at 855-284-4642 as well as follow the Patient Advocacy Navigator online at FacebookTwitter, and Google+. You can also reach her via emailIf you’d like to see your recap or news release included in this sampling, let her know!

3 Comments leave one →
  1. December 20, 2011 11:32 am

    As a (patient, survivor, soon to be activist), I appreciate the time you take to keep those of us who are so inclined in the loop. With San Antonio and ASH back to back like this, it is hard for someone with a disorganized and easily distracted brain from finding the news that is most pertinent to me.

    Just wanted to take the time to say thanks!


    • December 21, 2011 5:51 pm


      Thank you so much for taking the time to comment! Please let me know via Twitter or our other networks if there is anything you would like to see me/us cover here on our blog. I am pleased that we are listed on your blogroll!

      Thanks again.


  1. Our 2011 American Society of Hematology (ASH) Coverage: Part 2 « Diplomat Specialty Pharmacy

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

%d bloggers like this: